We are an oncology company focused on the clinical development of novel therapies for cancer. Our lead programs include a potential best-in-class HDAC inhibitor, Pracinostat, a novel mitochondrial inhibitor, ME-344, and a PI3K-delta inhibitor, PWT143.
[ Read more ]
MEI Pharma Receives Orphan Status for Pracinostat for Treatment of AML
[ February 28, 2014 ]
MEI Pharma Initiates Phase II Trial of Pracinostat in Refractory MDS
[ January 14, 2014 ]
Click here for our 2013 Annual Review